Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 10 of 30 for:    Dermatophagoides pteronyssinus AND Dermatophagoides farinae

Evaluation of the Effect of a Nasal Allergen Challenge With Dermatophagoides Farinae Extract on Nasal Airway Inflammation in Allergic Individuals, Comparing E-cigarette Users to Cigarette Smokers and Non-smokers. (Mitey Nose)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03023397
Recruitment Status : Terminated (Lack of funding)
First Posted : January 18, 2017
Last Update Posted : September 21, 2018
Sponsor:
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
University of North Carolina, Chapel Hill

Brief Summary:
The purpose of this pilot study is to evaluate allergen-induced nasal airway inflammation following nasal application of Dermatophagoides farinae (Der f), or house dust mite, extract in e-cigarette users, cigarette smokers, and non-smokers.

Condition or disease Intervention/treatment Phase
Healthy Participants Tobacco Smokers Biological: Der f Phase 1

Detailed Description:

The recent increase in popularity of e-cigarettes for smoking cessation or in combination with conventional cigarettes has led to safety concerns regarding their potential role in respiratory disease. These tobacco alternative devices were initially perceived as a "safer" alternative to cigarettes and were marketed without much known about their health effects. Increasing evidence demonstrates that while they contain fewer toxins and carcinogens than conventional cigarettes, they do involve delivery of ultrafine particles to the lower airways and can contain heavy metals and other chemicals. Tobacco smoke may augment allergic inflammation resulting from allergic rhinitis and/or asthma. Animal models of allergic asthma demonstrate aggravation of allergen-induced airway inflammation following inhalation of e-cig cartridge solution, with increased airway eosinophil infiltration, production of Th2 cytokines, and airway hyperresponsivness. In vitro studies in human tissues have demonstrated pro-inflammatory responses to e-cig vapour extract yet have not evaluated the effects of e-cig usage on allergic inflammation in human airways. Current evidence suggests that e-cigarette use augments allergic inflammatory responses in a similar way as tobacco smoke, yet a head-to-head comparison of the effects of these two exposures has not been performed in humans.

Use of tobacco products remains a pervasive problem in our society and around the world, with significant impact on respiratory health and quality of life. With the emergence of new non-tobacco based nicotine products like e-cigarettes, it is important to understand the impact these substances have on respiratory health and disease. The aim of this study is to study the impact of these products on allergic inflammation in house dust mite-allergic subjects who already routinely use e-cigarettes and to compare their responses to those of cigarette smokers and non-smokers. A thorough understanding of the potential health impacts of tobacco alternative substances is needed, especially given the rising popularity of such products with adolescents and young adults to whom these substances have particular appeal given their purported "safety" and variety of flavors to choose from.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Evaluation of the Effect of a Nasal Allergen Challenge With Dermatophagoides Farinae Extract on Nasal Airway Inflammation in Allergic Individuals, Comparing E-cigarette Users to Cigarette Smokers and Non-smokers.
Actual Study Start Date : March 27, 2017
Actual Primary Completion Date : April 16, 2018
Actual Study Completion Date : April 23, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: E-Cigarettes

Arm Intervention/treatment
Der f treated Non-smoker Biological: Der f
Nasal administration of Dermatophagoides farinae with 100 allergen units (AU), 500 AU, and finally 1000 AU
Other Name: (Der f)

Der f treated Cigarette smoker Biological: Der f
Nasal administration of Dermatophagoides farinae with 100 allergen units (AU), 500 AU, and finally 1000 AU
Other Name: (Der f)

Der f treated E-cig user Biological: Der f
Nasal administration of Dermatophagoides farinae with 100 allergen units (AU), 500 AU, and finally 1000 AU
Other Name: (Der f)




Primary Outcome Measures :
  1. Change in eosinophils/mL in nasal lavage fluid (NLF) [ Time Frame: Pre- and 4 hours post- nasal allergen challenge ]
    NLF will be collected immediately prior to administration of the nasal allergen challenge. 4 hours after administration of a bolus provocative dose of allergen (determined at screening day visit nasal allergen challenge), NLF will be collected. Pre- and 4 hours post- challenge NLF will be analyzed for cellularity. Values will be compared across e-cigarette smokers, tobacco cigarette smokers, and non-smokers.

  2. Change in eosinophilic cationic protein (ECP) levels in epithelial lining fluid (ELF) [ Time Frame: Pre- and 4 hours post- nasal allergen challenge ]
    ELF will be collected immediately prior to administration of the nasal allergen challenge. 4 hours after administration of a bolus provocative dose of allergen (determined at screening day visit nasal allergen challenge), ELF will be collected. Pre- and 4 hours post- challenge ELF will be analyzed for ECP levels. Values will be compared across e-cigarette smokers, tobacco cigarette smokers, and non-smokers.


Secondary Outcome Measures :
  1. Nasal lavage fluid cytokines [ Time Frame: Pre- and 4 hours-post nasal allergen challenge ]
    NLF will be collected immediately prior to administration of the nasal allergen challenge, and 4 hours post- nasal allergen challenge. Cytokine levels will be quantified with commercially available ELISAs.

  2. Nasal epithelial cell messenger ribonucleic acid (mRNA) [ Time Frame: Baseline (within two months of nasal allergen challenge) and 4 hours post- nasal allergen challenge ]
    Nasal epithelial cell biopsies will be collected at baseline (within two months of nasal allergen challenge), and 4 hours post- nasal allergen challenge. Gene expression changes will be quantified using qRT-PCR.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Specific allergy to house dust mite D. farinae confirmed by positive immediate skin test response
  2. Subjects will either be non-asthmatic or have mild asthma characterized by an Forced expiratory volume in one second (FEV1) of at least 80% of predicted to Forced vital capacity (FVC) ratio of at least .75
  3. Subjects will be classified as tobacco smokers, e-cigarette users, or non-smokers according to the following guidelines.
  4. Ability to withhold antihistamine medications for one week prior to baseline and allergen challenge visits
  5. Subjects must be able and willing to give informed consent.

Exclusion Criteria:

  1. Any chronic medical condition considered by the PI as a contraindication to the allergen challenge study including significant cardiovascular disease, diabetes requiring medication, chronic renal disease, bleeding disorder, or chronic thyroid disease.
  2. Physician directed emergency treatment for an asthma exacerbation within the preceding 12 months.
  3. Use of systemic steroid therapy within the preceding 12 months for treatment of an asthma exacerbation.
  4. Use of inhaled or nasal steroids, cromolyn or leukotriene receptor antagonists (Montelukast or zafirlukast ) within the past month (except for use of cromolyn exclusively prior to exercise).
  5. Subjects who smoke marijuana or use illicit drugs will be excluded.
  6. Use of daily theophylline within the past month.
  7. Use of nasal medications that might alter the response to nasal allergen challenge including anti-inflammatory and anti-histamine agents within one week of challenge.
  8. Inability to withhold inhaled or oral bronchodilator medications for 12 hours prior to allergen challenge.
  9. Pregnancy or nursing a baby.
  10. Women of child-bearing age who are not using dependable contraception (such as birth control pills, intrauterine device (IUD), estrogen patches) or who are not completely abstinent.
  11. Nighttime symptoms of cough or wheeze greater than 1x/week at baseline (not during a clearly recognized viral induced asthma exacerbation) which would be characteristic of a person of moderate or severe persistent asthma as outlined in the current NHLBI guidelines for diagnosis and management of asthma.
  12. Exacerbation of asthma more than 2x/week which would be characteristic of a person with moderate or severe persistent asthma as outlined in the current NHLBI guidelines for diagnosis and management of asthma.
  13. Daily requirement for albuterol due to asthma symptoms (cough, wheeze, chest tightness) which would be characteristic of a person of moderate or severe persistent asthma as outlined in the current NHLBI guidelines for diagnosis and management of asthma. (Not to include prophylactic use of albuterol prior to exercise).
  14. Viral upper respiratory tract infection or other acute inflammatory conditions of the nose or paranasal sinuses, such as sinusitis, within 4 weeks of challenge.
  15. Any acute infection requiring antibiotics within 4 weeks of challenge.
  16. Participating in an allergen inhalation study within 2 weeks of this challenge or use of any other investigational agent within the last 30 days.
  17. Use of tricyclic antidepressants or beta-blockers.

    -


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03023397


Locations
Layout table for location information
United States, North Carolina
UNC Center for Environmental Medicine, Asthma and Lung Biology
Chapel Hill, North Carolina, United States, 27599-7310
Sponsors and Collaborators
University of North Carolina, Chapel Hill
National Heart, Lung, and Blood Institute (NHLBI)
Investigators
Layout table for investigator information
Principal Investigator: Michelle Hernandez, MD University of North Carolina

Layout table for additonal information
Responsible Party: University of North Carolina, Chapel Hill
ClinicalTrials.gov Identifier: NCT03023397     History of Changes
Other Study ID Numbers: 16-1622
P50HL120100-05 ( U.S. NIH Grant/Contract )
First Posted: January 18, 2017    Key Record Dates
Last Update Posted: September 21, 2018
Last Verified: September 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by University of North Carolina, Chapel Hill:
E-cig smokers

Additional relevant MeSH terms:
Layout table for MeSH terms
Inflammation
Pathologic Processes